In the wake of the release of update guidelines from the European Hypertension Society (ESH) guidelines on the management of arterial hypertension, Medtronic has issued a statement expressing its “excitement” over the inclusion of renal denervation as a part of the hypertension care pathway.
The guidelines, which were presented for the first time during during the ESH’s 32nd annual European meeting on hypertension and cardiovascular protection (24–26 June, Milan, Italy) state that renal denervation can be proposed as an adjunctive therapy in select patients with resistant hypertension.
According to Medtronic, the statement marks a turning point for renal denervation as a hypertension treatment and supports its use as a safe and effective complementary treatment option in reducing blood pressure for patients, in addition to medications and lifestyle changes.
“These new clinical guidelines in Europe reinforce the safety and effectiveness of renal denervation as a third pillar for difficult to control hypertension—along with lifestyle changes and medication,” said Jason Weidman, senior vice president and president of the Coronary and Renal Denervation business at Medtronic. “This is a positive step forward for the Symplicity Blood Pressure Procedure and underscores the desire of the clinical community to include new treatment options to improve hypertension control rates.”
Medtronic is continuing clinical programmes with the SPYRAL AFFIRM and GSR-DEFINE studies. Its Symplicity Spyral system is approved for commercial use in more than 60 countries but is currently limited to investigational use in USA, Japan and Canada.
